Edition:
United States

Akari Therapeutics PLC (AKTX.OQ)

AKTX.OQ on NASDAQ Stock Exchange Capital Market

2.03USD
12:28pm EDT
Change (% chg)

$-0.01 (-0.49%)
Prev Close
$2.04
Open
$2.05
Day's High
$2.08
Day's Low
$1.97
Volume
3,945
Avg. Vol
12,696
52-wk High
$11.90
52-wk Low
$1.71

Chart for

About

Akari Therapeutics, Plc, formerly Celsus Therapeutics Plc, is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases caused by dysregulation of complement component 5 (C5), including paroxysmal nocturnal... (more)

Overall

Beta: -7.47
Market Cap(Mil.): $31.12
Shares Outstanding(Mil.): 0.15
Dividend: --
Yield (%): --

Financials

  AKTX.OQ Industry Sector
P/E (TTM): -- 103.50 32.14
EPS (TTM): -1.83 -- --
ROI: -124.27 1.52 12.66
ROE: -124.76 0.25 14.84

BRIEF-David Horn Solomon Resigns As CEO Of Akari Therapeutics

* AKARI THERAPEUTICS SAYS ON MAY 8, DAVID HORN SOLOMON, RESIGNED AS CEO AND AS A MEMBER OF BOARD EFFECTIVE IMMEDIATELY - SEC FILING

May 11 2018

BRIEF-Akari Therapeutics Qtrly Loss Per Common Share $0.01

* AKARI THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT CLINICAL PROGRESS

Mar 21 2018

Earnings vs. Estimates